MBMahmoud El Badry

Mahmoud El Badry

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mahmoud El Badry has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supramolecular stabilization of β-cyclodextrin–dendrimer/siRNA polyplexes using adamantane-functionalized cystamine polyethylene glycol

    by Mahmoud H. Othman, Khaled I. Saleh, Mahmoud El-Badry

    The development of nonviral carriers that simultaneously provide extracellular stability and efficient intracellular release remains a major challenge for small interfering RNA (siRNA) delivery. In this study, we developed a biocleavable supramolecular system by combining adamantane-functionalized cystamine-poly(ethylene glycol) (Ad-CYS-PEG) with a β-cyclodextrin–polyamidoamine dendrimer conjugate (β-CDE) through host–guest interactions. The resulting Ad-CYS-PEG/β-CDE complexes were designed to stabilize siRNA polyplexes under extracellular conditions while allowing intracellular dissociation through reduction of disulfide linkages. Successful synthesis of Ad-CYS-PEG was confirmed by 1H NMR spectroscopy. Agarose gel electrophoresis with heparin competition demonstrated enhanced polyplex stability compared with β-CDE alone, indicating stronger siRNA complexation following supramolecular assembly. Flow cytometric analysis using KB cells showed increased cellular uptake of Ad-CYS-PEG/β-CDE/siRNA complexes relative to β-CDE/siRNA polyplexes. Furthermore, the modified complexes exhibited negligible cytotoxicity under the experimental conditions evaluated. These findings demonstrate that biocleavable supramolecular complexation with Ad-CYS-PEG effectively improves the stability and cellular uptake of β-CDE-based siRNA polyplexes while maintaining favorable cytocompatibility. This host–guest assembly strategy represents a simple and adaptable platform for the design of biodegradable nonviral siRNA delivery systems and provides a foundation for future optimization toward functional gene silencing applications.

  • Nanoparticle-Based Vaccines: From Design and Immune Modulation to Clinical Translation

    by Nada M. Elfeky, Merna G. Khalaf, Noha G. Morsi, Heba A. Fathi, Safy Hadiya, Omnia H.M. Omar, Gihan Fetih, Sherif I. Kamel, Mahmoud Elbadry

    Vaccines are one of the most notable developments in modern medicine, and their role in combating and even eradicating diseases cannot be overlooked. Through an immunological cascade, vaccines produce an immunological memory response evident by memory cells and antibodies formation. Ever since the introduction of the first vaccine against smallpox, great efforts have been made to further improve vaccine efficacy, overcome limitations, and develop vaccines against emerging pathogens. The utilization of nanotechnology in vaccines has many benefits, as nanotechnology can address most of the limitations of traditional vaccines. Moreover, it has paved the path for the development of several vaccinations and is expected to continue contributing to future advancements. Nanoparticles have several types, with each type having its advantages and drawbacks. The physicochemical characteristics of these nanoparticles, namely particle size, particle shape, particle rigidity, surface charge, and hydrophobicity, affect the immune response potency. Optimization of these properties can allow the manufacture of vaccines that trigger strong immune responses. This strategic optimization permitted the production of effective vaccine formulations against several major pathogens in the market. Notable nanoparticle vaccines include the human papillomavirus, malaria, hepatitis B, and severe acute respiratory syndrome coronavirus 2 vaccines. This comprehensive review explores the vaccine immunological cascade, the platforms of nanoparticles, their advantages and drawbacks, and the impact of their physicochemical characteristics on vaccine efficacy. Moreover, this review highlights the nanovaccine formulations that have been approved for use.